• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

‘Salty’ Concern: Tackling High Salt Consumption in China
Veena S. Kulkarni, Associate Professor, Department of Criminology, Sociology and Geography, Arkansas State University, USA; and Raghav Gaiha, (Hon.) Professorial Research Fellow, Global Development Institute, University of Manchester, England.By Veena S. Kulkarni and Raghav GaihaNEW DELHI, India and JONESBORO, US, Oct 7 2019 (IPS) China’s almost meteoric transition from a being a low income to a middle income country within a span of four decades is often perceived as a miracle analogous to the post Second World War Japanese economic development experience. China’s GDP rose from $200 current United States dollars (US$ ...
Source: IPS Inter Press Service - Health - October 7, 2019 Category: International Medicine & Public Health Authors: Veena Kulkarni and Raghav Gaiha Tags: Asia-Pacific Development & Aid Economy & Trade Food & Agriculture Food Sustainability Globalisation Headlines Health Labour TerraViva United Nations Barilla Center for Food and Nutrition Foundation (BCFN) Source Type: news

Reduction of Leukocyte Microvascular Adherence and Preservation of Blood-Brain Barrier Function by Superoxide-Lowering Therapies in a Piglet Model of Neonatal Asphyxia
Conclusion: Using three different strategies to either prevent formation or enhance elimination of O2⋅_ during the post-asphyxial period, we saw both reduced leukocyte adherence and preserved BBB function with treatment. These findings suggest that agents which lower O2⋅_ in brain may be attractive new therapeutic interventions for the protection of the neonatal brain following asphyxia. Introduction Asphyxia is a relatively common source of neonatal brain damage (1), affecting ~2 in every 1,000 births (2). The hypoxic ischemia resulting from this oxygen deprivation can produ...
Source: Frontiers in Neurology - April 30, 2019 Category: Neurology Source Type: research

Janssen Announces U.S. FDA Approval of INVEGA HAFYERA ™(6-month paliperidone palmitate), First and Only Twice-Yearly Treatment for Adults with Schizophrenia
TITUSVILLE, N.J., Sept. 1, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved long-acting atypical antipsychotic INVEGA HAFYERA™ (6-month paliperidone palmitate), the first-and-only twice-yearly injectable for the treatment of schizophrenia in adults. Before transitioning to INVEGA HAFYERA™, patients must be adequately treated with INVEGA SUSTENNA® (1-month paliperidone palmitate) for at least four months, or INVEGA TRINZA® (3-month paliperidone palmitate) for at least one 3-month injection cycle.1 The FDA approval of INVEGA ...
Source: Johnson and Johnson - September 1, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news